$MORF News
Last published 1y ago
- 1y agoBBNXBCAXKMTSMORF+2Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science CompaniesBusiness WireOmega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The
- 2y agoLLYMORFLilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel DiseasePR NewswireEli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a...
- 2y agoMORFPFCWSBCACNBKuehn Law Encourages MORF, PFC, WSBC, and ACNB Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoAMBCBESTINFNMORFKuehn Law Encourages MORF, AMBC, INFN, and BEST Investors to Contact Law FirmGlobeNewswireNEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoMORFMORF Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Morphic Holding to Eli LillyGlobeNewswireMONSEY, N.Y., July 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Morphic Holding, Inc. (NASDAQ:MORF) ("Morphic") to Eli Lilly and Company
- 2y agoLLYMORFLilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel DiseasePR NewswireEli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a...
- 2y agoMORFMorphic to Participate in Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today
- 2y agoMORFMorphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking CellsGlobeNewswire-α4β7 Inhibition Rapidly Increases the Rolling Velocity and Flux of B Cells in Gut-associated Lymphoid Tissues- -Impact of Potent and Selective Small Molecule Inhibitor Comparable to Monoclonal Antibody Activity-
- 2y agoMORFMorphic to Participate in RBC Capital Markets Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today
- 2y agoMORFMorphic Announces Corporate Highlights and Financial Results for the First Quarter 2024GlobeNewswire- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study
- 2y agoMORFMORF Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Morphic Holding, Inc. (NASDAQ:MORF)GlobeNewswireNEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (https://aftlaw.com/), a nationally recognized law firm that focuses on protecting investors' rights, is investigating whether Morphic
- 2y agoMORFMorphic Appoints Dr. Simon Cooper as Chief Medical OfficerGlobeNewswireWALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 2y agoMORFMorphic to Participate in March Investor ConferencesGlobeNewswireWALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today
- 2y agoMORFMorphic Announces Corporate Highlights and Financial Results for the Full Year 2023GlobeNewswire-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC-
- 2y agoMORFMorphic to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a
- 2y agoMORFMORF REMINDER: Robbins LLP is Investigating the Officers and Directors of Morphic Holdings, Inc.GlobeNewswireSAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ:MORF) to determine whether certain Morphic officers and directors violated
- 2y agoMORFRobbins LLP Reminds MORF Investors that it is Investigating Morphic Holdings, Inc. on Behalf of InvestorsBusiness WireShareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ:MORF) to determine whether certain Morphic officers and directors violated securities laws and breached fiduciary duties to
- 2y agoMORFMORF SHAREHOLDERS: Investors of Morphic Holdings, Inc. Should Contact Robbins LLP for Information About Our InvestigationGlobeNewswireSAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ:MORF) to determine whether certain Morphic officers and directors violated
- 2y agoMORFMorphic Holding, Inc. Reminder: Robbins LLP is Investigating MORF on Behalf of InvestorsBusiness WireShareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ:MORF) to determine whether certain Morphic officers and directors violated securities laws and breached fiduciary duties to
- 2y agoMORFMorphic Holding, Inc. Investors Should Contact Robbins LLP for Information About Our Investigation of MORFGlobeNewswireSAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Morphic Holding, Inc. (NASDAQ:MORF) to determine whether certain Morphic officers and directors violated
- 3y agoMORFMorphic to Present at November Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 3y agoMORFMorphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023GlobeNewswire-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative
- 3y agoMORFMorphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data SetGlobeNewswireWALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 3y agoMORFInvestigation of Morphic Holding, Inc. (MORF) Announced by Holzer & Holzer, LLCGlobeNewswireATLANTA, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Morphic Holding, Inc. ("Morphic" or "the Company") (NASDAQ:MORF) complied with federal securities laws. On September 22,
- 3y agoMORFMorphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of AbsenceGlobeNewswireWALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (NASDAQ:MORF) today announced that Chief Executive Officer Dr. Praveen Tipirneni suffered an emergent medical event and is taking a medical leave
- 3y agoMORFMorphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023GlobeNewswire-Orally administered MORF-057 achieved primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures- -Clinical improvement consistently seen across key measures at
- 3y agoMORFMorphic Announces Participation in 2023 Wells Fargo Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 3y agoMORFMorphic to Present at the Canaccord Genuity 43rd Annual Growth ConferenceGlobeNewswireWALTHAM, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today
- 3y agoMORFMorphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023GlobeNewswire-Reported positive topline results from EMERALD-1 study of MORF-057 in ulcerative colitis- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Greater than $730 million
- 3y agoMORFMorphic to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 3y agoMORFMorphic to Present at 2023 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 3y agoMORFMorphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative ColitisGlobeNewswireWALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF) today announced the presentation of new preclinical data in the MORF-057 IBD development program that are consistent with previous
- 3y agoMORFMorphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireWALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. ("Morphic"), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today
- 3y agoMORFMorphic Therapeutic Announces Pricing of $240.0 Million Public OfferingGlobeNewswireWALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (NASDAQ:MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today
- 3y agoMORFMorphic Therapeutic Announces Proposed Public OfferingGlobeNewswireWALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (NASDAQ:MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, today
- 3y agoMORFMorphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory MeasuresGlobeNewswire-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical remission by Modified Mayo
- 3y agoMORFMorphic Announces Corporate Highlights and Financial Results for the First Quarter 2023GlobeNewswire-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements across secondary and exploratory measures with no safety signal
- 3y agoMORFMorphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023GlobeNewswireWALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 3y agoMORFMorphic to Present at TD Cowen 43rd Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today
- 3y agoMORFMorphic Announces Corporate Highlights and Financial Results for the Full Year 2022GlobeNewswire-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis-
- 3y agoMORFMorphic to Present at SVB Leerink Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today
- 3y agoMORFMorphic to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today
- 3y agoMORFMorphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative ColitisGlobeNewswireWALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 4y agoMORFMorphic Announces Participation in 2022 Jefferies London Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 4y agoMORFMorphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022GlobeNewswireCompleted enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule EMERALD-2 phase 2b global randomized study of MORF-057 to begin fourth quarter WALTHAM, Mass., Nov.
- 4y agoMORFMorphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022GlobeNewswireSaturating receptor occupancy at 100 and 200 mg BID doses Statistically significant effects on key lymphocyte subsets WALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a
- 4y agoMORFMorphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of ProjectionsGlobeNewswireWALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases,
- 4y agoMORFMorphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022GlobeNewswire200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor WALTHAM, Mass., Oct. 10,
- 4y agoMORFMorphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award HonoreeGlobeNewswireRecognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders Founder, Director, and Scientific Advisory Board member of Morphic Therapeutic WALTHAM, Mass., Sept. 28, 2022 (G
- 4y agoMORFMorphic Celebrates Foundational Integrin Research Published in CellGlobeNewswirePaper describes key insight into integrin conformation, overcoming critical drug development challenge Company lauds Tim Springer, PhD, scientific founder of Morphic and Fu-Yang "Albert" Lin, PhD, first company employee WALTHAM, Mass., Sept. 2